Table 1.
Characteristics of lectures across different board review lectures
| All specialties | ASH (N = 75) | B & MDA (N = 288) | B & DF (N = 116) | GW (N = 300) | MSKCC (N = 199) | SCCA (N = 246) | P value | Overall (N = 1224) |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Women | 43.0 (57.3%) | 109 (37.8%) | 38.0 (32.8%) | 85.0 (28.3%) | 75.0 (37.7%) | 111 (45.1%) | <0.001 | 461 (37.7%) |
| Men | 32.0 (42.7%) | 179 (62.2%) | 78.0 (67.2%) | 215 (71.7%) | 124 (62.3%) | 135 (54.9%) | — | 763 (62.3%) |
| Specialty | ||||||||
| ABIM | 64.0 (85.3%) | 226 (78.5%) | 98.0 (84.5%) | 244 (81.3%) | 179 (89.9%) | 205 (83.3%) | — | 1016 (83.0%) |
| Others | 2.00 (2.7%) | 36.0 (12.5%) | 4.00 (3.4%) | 40.0 (13.3%) | 20.0 (10.1%) | 41.0 (16.7%) | — | 143 (11.7%) |
| Pathology | 1.00 (1.3%) | 15.0 (5.2%) | 6.00 (5.2%) | 12.0 (4.0%) | 0 (0%) | 0 (0%) | — | 34.0 (2.8%) |
| Pediatrics | 8.00 (10.7%) | 11.0 (3.8%) | 8.00 (6.9%) | 4.00 (1.3%) | 0 (0%) | 0 (0%) | — | 31.0 (2.5%) |
| ABIM | ASH (N = 64) | B & MDA (N = 226) | B & DF (N = 98) | GW (N = 244) | MSKCC (N = 179) | SCCA (N = 2 05) | P value | Overall (N = 1016) |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Women | 36.0 (56.3%) | 80.0 (35.4%) | 34.0 (34.7%) | 66.0 (27.0%) | 64.0 (35.8%) | 89.0 (43.4%) | <0.001 | 369 (36.3%) |
| Men | 28.0 (43.8%) | 146 (64.6%) | 64.0 (65.3%) | 178 (73.0%) | 115 (64.2%) | 116 (56.6%) | — | 647 (63.7%) |
| Certification | ||||||||
| Heme | 19.0 (29.7%) | 28.0 (12.4%) | 12.0 (12.2%) | 52.0 (21.3%) | 21.0 (11.7%) | 23.0 (11.2%) | — | 155 (15.3%) |
| Oncology | 10.0 (15.6%) | 126 (55.8%) | 43.0 (43.9%) | 104 (42.6%) | 119 (66.5%) | 92.0 (44.9%) | — | 494 (48.6%) |
| Both | 32.0 (50.0%) | 66.0 (29.2%) | 36.0 (36.7%) | 79.0 (32.4%) | 39.0 (21.8%) | 78.0 (38.0%) | — | 330 (32.5%) |
| None | 3.00 (4.7%) | 6.00 (2.7%) | 7.00 (7.1%) | 9.00 (3.7%) | 0 (0%) | 12.0 (5.9%) | — | 37.0 (3.6%) |
| Role | ||||||||
| Benign hematology | 35.0 (54.7%) | 49.0 (21.7%) | 20.0 (20.4%) | 86.0 (35.2%) | 19.0 (10.6%) | 38.0 (18.5%) | — | 247 (24.3%) |
| Malignant hematology | 29.0 (45.3%) | 63.0 (27.9%) | 22.0 (22.4%) | 55.0 (22.5%) | 40.0 (22.3%) | 57.0 (27.8%) | — | 266 (26.2%) |
| Solid tumors | 0 (0%) | 114 (50.4%) | 48.0 (49.0%) | 96.0 (39.3%) | 113 (63.1%) | 100 (48.8%) | — | 471 (46.4%) |
| Others | 0 (0%) | 0 (0%) | 8.00 (8.2%) | 7.00 (2.9%) | 7.00 (3.9%) | 10.0 (4.9%) | — | 32.0 (3.1%) |
ABIM, American Board of Internal Medicine; SCCA, Seattle Cancer Care Alliance; ASH, American Society of Hematology; B & MDA, Baylor College of Medicine and M.D. Anderson Cancer Center; B&DF, The Brigham and Dana-Farber; GW, George Washington School of Medicine and Health Sciences; MSKCC, Memorial Sloan-Kettering Cancer Center.